New drug cocktail shows promise for myeloma patients
NCT ID NCT05392946
First seen Oct 31, 2025 · Last updated May 17, 2026 · Updated 27 times
Summary
This study tests a new drug called iberdomide combined with three other cancer drugs (daratumumab, bortezomib, and dexamethasone) in people newly diagnosed with multiple myeloma. The goal is to find the best dose of iberdomide and see how well the combination works at killing cancer cells. About 49 adults with active myeloma who have not had prior treatment are participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.